FDA slaps down BioMarin’s Duchenne’s drug as rival nears a moment of truth

John Carroll

After outlining its objections to BioMarin's application for its experimental Duchenne muscular dystrophy drisapersen in an internal review and hearing clear objections from outside experts, the FDA has rejected the biotech's marketing application, saying it has yet to see real evidence of efficacy.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS